Tumour Indication MET status (copy number) Other known mutations Once-daily dose that delivers as near to tumour growth stasis as tested [mg (TG)] Time above pMET EC90 required to deliver tumour stasis (hours) Reference
EBC-1
Squamous NSCLC
CN gain (14)
P53, ATM
30 (76–94%)
12
(Jones et al., 2018) This study
NCI-H1993
NSCLC
CN gain (14)
P53, STK11
>30 (65%)
14.5
(Henry et al., 2016) Data on file
NCI-H441 NSCLC CN gain (3) P53, KRAS 100 (89%) 23 Data on file
HLXF-036LN NSCLC CN gain (3.7) P53 50 (-28%) 18 (Henry et al., 2016)
RCC43b PRCC CN gain (8) BRCA1 m 10 (100%) 10 (Schuller et al., 2015)
RCC47 PRCC CN gain (9) 2.5 (89%) 6 (Schuller et al., 2015)
SNU-5 Gastric CN gain (17.9) P53, IDH2, CDH1 5 (97%) 8 (Cui et al., 2011)
Hs746T Gastric CN gain (21.3) P53, BRCA, APC 2.5 (97%) 6 (Gavine et al., 2015)
MKN-45 Gastric CN gain (21) p53 25 (100%) 11 This study
NCI-H820 NSCLC CN gain (6) P53, STK11 >30 (73%) 12 Data on file